> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 32Co Launches Extensive UK Sleep Centre Network To Tackle Growing Sleep Disorder Crisis
- URL: https://med-techinsights.com/32co-launches-uk-sleep-centre-network-to-tackle-sleep-apnoea/
- Published: 2025-07-28T08:00:39.000Z
- Updated: 2026-10-22T07:47:06.000Z
- Description: London-based healthtech company 32Co will launch a nationwide network of sleep centres this summer to treat patients with mild to moderate obstructive sleep apnoea (OSA) and problematic snoring – transforming the treatment pipeline by granting patients access to previously scarce treatment devices.
- Author: Oliver Johnson
- Tags: Medical Device Manufacturing, News

London-based healthtech company [**32Co**](http://www.32co.com/?ref=med-techinsights.com) will launch a nationwide network of sleep centres this summer to treat patients with mild to moderate obstructive sleep apnoea (OSA) and problematic snoring – transforming the treatment pipeline by granting patients access to previously scarce treatment devices.

32Co will launch the first pilot centres in London, Manchester, Edinburgh, and Bristol, with new centres to launch nationwide and a national waitlist now open for patients in other regions. This marks a major progression in the treatment of OSA and problematic snoring in the UK where millions are currently either: undiagnosed, stuck in years-long NHS waiting lists, or without access to specialist treatment. 

The sleep centres, named ‘Aerox Sleep Centres’, will significantly improve access to Mandibular Advancement Devices (MADs) – a non-invasive, retainer device used to keep airways open during sleep. Though an effective treatment for OSA and snoring, the supply provision of these devices has previously been limited.

MADs are an [effective treatment against snorin](https://www.dentalcare.com/en-us/ce-courses/ce578/mad-effectiveness?ref=med-techinsights.com)[g](https://www.dentalcare.com/en-us/ce-courses/ce578/mad-effectiveness?ref=med-techinsights.com) which, until now, has had limited scientifically-backed treatment alternatives. MADs also serve as an alternative to industry-standard Continuous Positive Airway Pressure (CPAP) machines, as the non-invasive retainers can be easier to adhere to in place of CPAP masks.

For example, patients typically use MADs for 6.5hrs per night vs CPAP 5.2hrs per night, [indicating 25% higher adherence for MADs](https://jtd.amegroups.org/article/view/17794/html?ref=med-techinsights.com). The higher efficacy of CPAP is offset by greater MAD compliance, with CPAP and MAD achieving [similar improvements in EDS and QoL.](https://www.atsjournals.org/doi/10.1164/rccm.201212-2223OC?ref=med-techinsights.com)

The challenge has been access – MADs can only be prescribed by dental clinicians, not medical professionals. Yet, it’s estimated that <0.5% of dentists offer this treatment. 32Co is upskilling dentists in OSA treatment, giving them access to medical specialists for virtual collaboration and creating a market for MADs – enabling affected patients to receive NICE-approved treatment at practices local to them.

32Co Founder and CEO, Dr Sonia Szamocki said: “Our specialist platform and clinician network has already enabled specialist orthodontic treatments to be delivered locally across the UK. Now, we’re tackling the growing sleep disorder crisis in the UK, utilising the same platform to upskill dentists in obstructive sleep apnoea and problematic snoring treatment. In creating a network of localised sleep centres and curating a marketplace for custom made treatment devices, we are truly creating a gap in the market.”

The Aerox Sleep Centre network marks a major expansion into 32Co’s second healthcare vertical as the company continues to provide local access to specialist care. 32Co has already improved patient access to specialist orthodontic services across the UK, with 32Co dentists within 20 minutes of 90% of the UK.

The expansion is supported by Professor Ama Johal, former Vice-President of the British Society Dental Sleep Medicine. Now serving as Clinical Lead at 32Co, Professor Johal is a world renowned Dental Sleep Medicine expert, with a PhD in the use of Mandibular Advancement Splints in sleep-related breathing disorders.

32Co Clinical Lead, Professor Ama Johal: “Obstructive sleep apnoea and problematic snoring continues to plague millions of people across the UK and is linked with several serious medical conditions. Despite this, patient access to obstructive sleep apnoea and problematic snoring treatment is limited. 32Co’s Aerox Sleep Centres will deliver industry-backed treatment at the convenience of local practices, marking a significant change in the way millions of patients can receive treatment.”

OSA is a disorder where a person’s breathing stops for a short time during sleep, usually when the throat muscles relax and block their airway. Around 8 million people aged 30–69 years might be affected by OSA in the UK alone ([Lancet, 2020](https://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2819%2930449-7/fulltext?ref=med-techinsights.com)). OSA is linked with serious medical conditions, with [prevalence as high as 40% to 80%](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000988?ref=med-techinsights.com) in patients with hypertension, heart failure, coronary artery disease, pulmonary hypertension, atrial fibrillation, and stroke.

A further 1 in 4 in the UK snore or snore problematically, affecting sleep cycles and potentially leading to chronic sleep disruption which is linked to depression, memory loss, diabetes, and fatigue-related accidents. Snoring also contributes to a major cultural shift known as ‘sleep divorces’. Research from the [Sleep Prioritisation Survey](https://www.thetimes.com/life-style/sex-relationships/article/sleep-divorce-habits-productivity-happiness-lsd5gg0rp?ref=med-techinsights.com) revealed that 19% of millennials and 14% of Gen Z sleep in another room consistently.

The industry standard treatment method against sleep apnoea is via CPAP machine, which involves wearing a mask during sleep that is connected to a machine delivering a continuous flow of pressurised air. However, due to the intrusive nature of the CPAP machine, many patients find the mask uncomfortable, claustrophobic, and difficult to travel with, forcing them to stop treatment. For snoring, traditional over the counter solutions have failed to address the root cause.

In pre-pilot trials, the Aerox Sleep Centres and MADs have already helped hundreds of patients to improve their sleep, with 80% of the patients 32Co spoke to admitting they would be very disappointed if they could no longer use their sleep devices.

John, 69, Manchester said: “If it broke, I’d be back sleeping downstairs with the dog. I would be extremely disappointed.”

Helen, 64, London said: “I think lots of people would benefit because it’s very unobtrusive, and more people suffer from snoring than they realise.”

Michael, 58, London said: “I don’t wake up as tired as I normally do. Without it, I would probably wake up with less energy and be grumpier.”